• CA-074 Me: Precision Cathepsin B Inhibitor for Cell Death St

  2026-06-05

  CA-074 Me empowers researchers to achieve highly selective, reproducible inhibition of cathepsin B in apoptosis, necroptosis, and inflammation models. Its cell-permeable, methyl ester design and robust performance in both in vitro and in vivo systems give it an edge for dissecting lysosomal protease pathways and advancing mechanistic discovery.

• FOXA1–PUS1–EIF3b Axis Drives Prostate Cancer Bone Metastasis

  2026-06-05

  This study identifies a non-enzymatic mechanism by which PUS1, under the transcriptional control of FOXA1, stabilizes EIF3b and promotes bone metastasis in prostate cancer. The findings reveal a critical pathway and suggest new molecular targets for intervention in advanced prostate cancer.

• WSP-5 for Live-Cell Imaging of Hydrogen Sulfide Dynamics

  2026-06-04

  WSP-5 (Washington State Probe-5) delivers rapid, sensitive detection of hydrogen sulfide in cellular systems, enabling precise monitoring of H2S dynamics during disease modeling and drug discovery. Its improved activation kinetics and selectivity empower researchers to visualize subtle or transient H2S changes, surpassing previous probes for live-cell and cancer model studies.

• Angiotensin II: Mechanistic Powerhouse in Translational Vasc

  2026-06-04

  This thought-leadership article positions Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) as a mechanistic and strategic cornerstone for translational researchers investigating vascular remodeling, hypertension mechanisms, and cardiovascular pathology. Through the integration of current evidence—including the nuanced role of the renin–angiotensin system in viral infection—this piece advances the field beyond conventional product summaries. It offers actionable protocol guidance, a critical competitive landscape review, and a forward-looking synthesis on cross-domain translation and clinical implications.

• KIR2.1 Inhibition Reduces PASMC Proliferation and Migration

  2026-06-03

  This article reviews recent evidence demonstrating that inhibition of the Kir2.1 potassium channel attenuates proliferation and migration of pulmonary artery smooth muscle cells (PASMCs), key processes in pulmonary vascular remodeling and pulmonary hypertension (PH). The discussed study clarifies Kir2.1’s mechanistic role and identifies it as a promising target in cardiovascular ion channel research.

• (S)-Mephenytoin: Benchmark CYP2C19 Substrate in Drug Metabol

  2026-06-03

  (S)-Mephenytoin is a gold-standard CYP2C19 substrate, supporting reproducible cytochrome P450 metabolism assays. Its robust enzyme kinetics, compatibility with advanced in vitro models, and precise protocol parameters make it a key tool for pharmacokinetic studies.

• Crystal Structure of SLEV RNA Helicase and Inhibitor Discove

  2026-06-02

  This study reports the first high-resolution crystal structure of the Saint Louis encephalitis virus (SLEV) RNA helicase, a key viral replication enzyme. By characterizing its domain architecture and identifying potential inhibitors, the research lays a foundation for targeted antiviral strategies against SLEV and related flaviviruses.

• 5X Protein Loading Buffer (Reducing) for Consistent SDS-PAGE

  2026-06-02

  5X Protein Loading Buffer (Reducing) simplifies protein sample preparation for SDS-PAGE by ensuring thorough denaturation and reduction of disulfide bonds. It is ideal for workflows requiring accurate protein separation by molecular weight, but should not be used where native protein structure or non-reducing conditions are required.

• BFH772 (VEGFR2 inhibitor): Technical Guidance and Protocols

  2026-06-01

  BFH772 is a highly selective VEGFR2 inhibitor that enables targeted modulation of VEGFR2-mediated angiogenesis, especially in tumor research models. It is not suitable for workflows demanding water solubility or broad-spectrum kinase inhibition, making it critical to align experimental design with its defined solubility and selectivity characteristics.

• Bafilomycin C1: Precision Vacuolar H+-ATPases Inhibitor in A

  2026-06-01

  Bafilomycin C1 stands as a gold-standard vacuolar H+-ATPases inhibitor, enabling high-fidelity interrogation of autophagy, apoptosis, and membrane transporter signaling. Its integration into advanced phenotypic screens—such as high-content imaging with iPSC-derived models—unlocks robust mechanistic insight and workflow optimization for drug discovery and disease modeling.

• Applied Workflows with CA-074: Cathepsin B Inhibitor in Cell

  2026-05-31

  CA-074, a selective cathepsin B inhibitor, empowers researchers to dissect necroptosis, cancer metastasis, and neurotoxicity with unmatched specificity. Explore optimized protocols, troubleshooting strategies, and actionable insights for deploying CA-074 in advanced disease pathway investigations.

• EZ Cap™ Human PTEN mRNA (ψUTP): Precision Engineering for Tr

  2026-05-30

  Explore how EZ Cap™ Human PTEN mRNA (ψUTP), a cutting-edge in vitro transcribed mRNA, advances cancer research by integrating Cap 1 and pseudouridine modifications for enhanced stability and immune evasion. This article delivers a unique, protocol-focused analysis and critically examines breakthrough findings in nanoparticle-mediated mRNA delivery.

• Universal HPLC Method for Dual-Loaded Liposome Encapsulation

  2026-05-29

  This study introduces a nanoparticle exclusion HPLC (nPEC) technique for determining the encapsulation efficiency of dual-loaded liposomes, regardless of drug physicochemical differences. The method enables accurate, reproducible assessment critical for optimizing combination drug delivery strategies in cancer chemotherapy research.

• Self-Assembling Virus-Mimics Enable Extrahepatic mRNA Delive

  2026-05-29

  This study introduces a modular, self-assembling enveloped virus-mimicking particle (EVMP) platform that enables targeted, efficient mRNA delivery to extrahepatic organs such as the lung and spleen. By integrating computational peptide engineering and customized phospholipid envelopes, the work overcomes major limitations of conventional lipid nanoparticles, expanding the translational potential of mRNA therapeutics for non-liver tissues.

• KAS-ATAC Sequencing: Mapping Accessible and ssDNA Genome Reg

  2026-05-28

  The referenced protocol details KAS-ATAC sequencing, which simultaneously maps physically accessible and single-stranded DNA (ssDNA) regions genome-wide. This method enables high-resolution profiling of regulatory DNA elements and transcriptional activity, offering a unique view of chromatin dynamics and gene regulation.

15665 records 1/1045 page Next 12345 下5页 Last page